Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

With AUROPHARMA's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 15.426934
debtToEquity 22.248000
earningsGrowth 0.076000
revenueGrowth 0.084000
grossMargins 0.579750
operatingMargins 0.151360
trailingEps 60.030000
forwardEps 75.115380

AUROPHARMA's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
AUROPHARMA's low Debt-to-Equity ratio means the company is not over-leveraged, highlighting its conservative use of debt. This suggests reduced financial risk and a stable balance sheet, making AUROPHARMA a financially resilient company with lower exposure to debt-related pressures.
With AUROPHARMA's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in AUROPHARMA's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

The price of Aurobindo Pharma Limited has repeatedly been close to the lower limit of price projections. This trend suggests that the stock may be underperforming, raising concerns among investors about future performance.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


Recent analysis shows a strong buy bias for AUROPHARMA, encouraging investors to view it as a solid investment option. The positive sentiment surrounding AUROPHARMA suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.